1 Comprehensive analysis of key m6A RNA modification-related

- 2 genes and immune infiltrates in hypertrophic cardiomyopathy
- 3 Xia Hu¹, Bo Liang²
- 4 1. Shanghai Jiaotong University, Shanghai, China
- 5 2. Xinqiao Hospital ,Chongqing, China
- 6 Correspondence: Dr. Bo Liang
- 7

8 Abstract

9 Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease. 10 We performed a comprehensive analysis to construct the correlation of m6A and 11 immune in HCM. Two HCM datasets (GSE141910 and GSE160997) and m6A-12 related regulators were obtained from GEO and published articles, respectively. 13 Differentially expressed m6A-related regulators were obtained. Random forest model 14 and nomogram were conducted to assess the risk of HCM, and finally, the m6A 15 subtype was constructed. Functional enrichment analysis was conducted. Protein-16 protein interaction network of differentially expressed genes between m6A subtypes 17 was performed. Furthermore, we constructed the Hubgene-chemical network, 18 Hubgene-microRNA network, and Hubgene-transcription factor network of the top 10 19 hubgenes. Additionally, the immune subtype and hubgene subtype were constructed. 20 PCR was performed to validate the m6A-related regulators. We obtained 20 m6A-21 related regulators in HCM. Among them, 8 m6A-related regulators differentially 22 expressed (YTHDC1, HNRNPC, and FMR1 were up-regulated while YTHDC2, FTO, 23 WTAP, IGF2BP2, and IGF2BP3 were down-regulated). FTO, FMR1, IGF2BP3, 24 YTHDC1, and IGF2BP2 were the top 5 important m6A-related regulators and were 25 used to conduct the nomogram. We obtained 329 differentially expressed genes in 26 m6A subtype and these genes enriched HCM-related processes and pathways. 27 Furthermore, we constructed the Hubgene-chemical network, Hubgene-microRNA

28	network, and Hubgene-transcription factor network of the top 10 hubgenes (NFKBIA,							
29	NFKB1, PSMA3, PSMC4, PSMA2, PSMA4, PSMD7, PSMD10, PSMD8, and							
30	PSMA6). And then we constructed an immune subtype based on the immune cell							
31	infiltration levels and hubgene subtype based on the expression of the top 10							
32	hubgenes. Finally, we verified the main results through experiments. In conclusion,							
33	we built a nomogram and identified 8 m6A-related regulators and 10 hubgenes, which							
34	were prominently associated with HCM. We found that m6A and the immune system							
35	may play a crucial role in the HCM. Accordingly, those genes and pathways might							
36	become therapeutic targets with clinical usefulness in the future.							
37								
38								
39								

40 Keywords: Hypertrophic cardiomyopathy; Epigenetics; N6-methyladenosine;
41 Immune; Bioinformatics

42 1. Introduction

43 Hypertrophic cardiomyopathy (HCM) is the commonest primitive inherited disease of 44 the myocardium^[1], with an autosomal dominant pattern of inheritance and a 45 worldwide prevalence of approximately one in 500 adult subjects[2, 3]. HCM is 46 defined principally by left ventricular hypertrophy without increased cardiac afterload 47 or another underlying pathophysiological etiology, and causes heart failure at any 48 age[4]. A clinical diagnosis of HCM in adults can be established by imaging with 2D 49 echocardiography or cardiovascular magnetic resonance[5]. According to the latest 50 guidelines^[2, 3], pharmacological therapy for HCM patients includes non-selective 51 drugs such as β -blockers, cardiac-selective calcium antagonists, and disopyramide, to 52 be used in symptomatic patients with obstruction of the left ventricular outflow tract. 53 Current drugs are unable to address the pathophysiological mechanisms of left 54 ventricular dysfunction in HCM and are not, therefore, effective in preventing 55 arrhythmias or slowing down disease progression in HCM patients[1]. Novel 56 allosteric inhibitors of myosin are being developed and clinically validated, 57 specifically targeting HCM-related pathophysiological mechanisms, such as 58 myocardial hypercontractility and altered energetics[6]. However, HCM is a 59 heterogeneous disease that involves numerous sarcomere-independent morphological 60 features, suggesting that the precise mechanisms of HCM have not been fully 61 elucidated.

62 Epigenetic dysregulation is crucial for the pathological development of cardiovascular 63 diseases[7, 8]. N6-methyladenosine (m6A) is the most common post-transcriptional 64 modification of mRNA[9] and has recently attracted great attention. m6A influences a 65 series of biological functions in cardiovascular diseases. m6A RNA modification 66 mediates the atherogenic inflammatory cascades in vascular endothelium[10] and 67 modulates endothelial atherogenic responses to disturbed flow in mice[11]. Age-68 related differences in m6A in response to acute myocardial ischemia/reperfusion 69 injury[12] and m6A might play important roles in blood pressure regulation[13]. m6A

modification effectively improves the cardiac function and decreases the infarct size in acute myocardial infarction through tricarboxylic acid cycle-based metabolic reprogramming[14] and promotes miR-133a repression during cardiac development and hypertrophy via IGF2BP2[15]. In heart failure, FTO-dependent cardiac m6A methylome plays a functional importance in cardiac contraction[16] and m6A might be an interesting target for therapeutic interventions[17]. However, the role of m6A in HCM is largely unknown.

77 m6A RNA modification acts as a novel regulator in both innate and adaptive immune 78 response[18, 19]. In acute myocardial infarction and aortic dissection, m6A is closely 79 connected to immune cell infiltration[20, 21]. Previous study showed that the changes 80 in the immune system engage in the HCM mechanisms[22, 23] and the systemic 81 immune-inflammation index is a significant risk factor for all-cause mortality in HCM 82 patients[24]. All these evidence supports immune response has a significant impact on 83 the HCM biology and outcome. However, the crosstalk between m6A and immune 84 response in HCM is poorly understood. In this study, we comprehensively evaluated 85 the expression of m6A-related regulators and immune cell infiltration in HCM 86 patients from two independent cohorts, constructed random forest model and 87 nomogram, and further identified m6A and immune subtype (Figure 1).

88

89 2. Methods

90 2.1 Data collection

Two HCM datasets from GEO, namely GSE141910 and GSE160997[25], were
obtained though the *GEOquery* package and details are shown in Table 1. All samples
were pooled after removing batch effects (Figure S1), as descried previously[26, 27].
In addition, m6A-related regulators were extracted based on published literature.

95 2.2 m6A-related regulators in HCM

96 The chromosomal locations of m6A-related regulators were visualized using the
97 *RCircos* package and the differential expression levels of m6A-related regulators
98 between HCM patients and the controls were analyzed using the *limma* package.

99 Finally, linear regression analysis was used to explore the correlation between m6A

100 writers and m6A erasers.

101 2.3 Construction of random forest model and nomogram

Random forest is a compositionally supervised learning method that can be viewed as an extension of decision tree[28]. We divided patients with HCM into the training cohort and the validation cohort by 7:3, and selected candidate m6A regulators from all m6A-related regulators to predict the occurrence of HCM. We built the random forest model in the training cohort with ntrees = 500, and then analyzed the importance of m6A-related regulators and evaluated the model with residual analysis and ROC curves on both training and validation cohorts.

We constructed a nomogram based on the top 5 candidate m6A regulators using the *rms* package to predict the prevalence of HCM patients. Calibration curve, decision curve analysis, and ROC curve were conducted to evaluate the nomogram, as described previously[29, 30]. Finally, we explored the correlation between top 5 candidate m6A regulators and immune-related cell types.

114 2.4 m6A subtype construction

We used the *ConsensusClusterPlus* package[31] to identify the membership and number of clusters in datasets based on the expression of the top 5 m6A-related regulators. Then individuals were clustered into corresponding clusters. We further analyzed the expression of the top 10 hubgenes in corresponding clusters. The differentially expressed genes among clusters were analyzed using the *limma* package with a threshold of adjusted P < 0.05 and $|log_2Fold$ Change| > 2 and the *ggplot2* package[26] was used to visualization.

We used the *clusterProfiler* package[32] to perform gene ontology (including cellular component, molecular function, and biological process) and Kyoto Encyclopedia of Genes and Genomes enrichment analysis on differentially expressed genes with a threshold of P < 0.5 and false discovery rate < 0.05. The specific Kyoto Encyclopedia of Genes and Genomes terms were visualized through the *Pathview* package[33]. Gene sets of c2.cp.v7.4.symbols.gmt, which are curated from various sources,

including online pathway databases and the biomedical literature, were downloaded from Molecular Signatures Database[34] as background for gene set enrichment analysis[35]. Adjusted P < 0.05 was considered statistically significant.

131 The STRING database[36] was used for protein-protein interaction analysis of 132 differentially expressed genes, and those genes with a score greater than 0.6 were 133 selected for later analysis. The cytoHubba plugin[37] in Cytoscape[38] was used to 134 functionally enrich the cluster from the protein-protein interaction network to obtain 135 the hubgenes. Furthermore, we constructed Hubgene-chemical network, Hubgene-136 microRNA network, and Hubgene-transcription factor network of the top 10 137 obtained the protein-protein hubgenes based on interaction network. 138 NetworkAnalyst[39] was used to build Hubgene-chemical network and Hubgene-139 chemical network, and miRTarBase[40] was used to build Hubgene-microRNA 140 network. Cytoscape[38] was used for visualization.

141 2.5 Immune subtype construction

142 We calculated the immune cell infiltration levels using the *ssGSEA* function of the 143 GSVA package to obtain the enrichment score for each immune-related cell type. 144 Subtype classification was further constructed based on the enrichment score features 145 of immune-related cell types using the ConsensusClusterPlus package[31]. Then 146 individuals were clustered into corresponding clusters. The differentially expressed 147 genes among clusters were analyzed using the *limma* package with a threshold of 148 adjusted P < 0.05 and $|\log_2$ Fold Change| > 2 and the ggplot2 package[26] was used to 149 visualization. We further analyzed the difference and correlation between top 10 150 hubgenes and immune infiltration.

151 CIBERSORT is a method for characterizing cell composition of complex tissues from 152 their gene expression profiles[41]. We obtained immune cell infiltration matrix by 153 CIBERSORT with P < 0.05 as threshold. The *ggplot2* package[26] and *corrplot* 154 package were used to visualization. We further analyzed the correlation between top 155 10 hubgenes and immune cells.

156 2.6 Hubgene subtype construction

Subtype classification was constructed based on the expression of top 10 hubgenes
using the *ConsensusClusterPlus* package[31]. Then individuals were clustered into
corresponding clusters. We further analyzed the expression of top 10 hubgenes in
corresponding clusters.

161 2.7 Experimental Validation

162 The 8-week-old C57BL/6J mice were obtained from Vital River (Beijing, China) and 163 all animal experiments were reviewed and approved by the Experimental Animal 164 Center of Zhengzhou University (Zhengzhou, China) (ZZU-LAC20220311[23]). We 165 conducted transverse aortic constriction (TAC) to build the myocardial hypertrophy 166 model[42]. A total of 12 male mice were divided into the Sham group (N = 6) and the 167 TAC group (N = 6). After four weeks of TAC, the mice were sacrificed after 168 transthoracic echocardiography for the following experiments. Histomorphological 169 changes in the heart were determined by HE and WGA staining according to our 170 previous protocol[43, 44]. The mRNA expression of atrial natriuretic peptide (Anp), 171 brain natriuretic peptide (Bnp), myosin heavy chain 7 (Myh7), Hnrnpc, Fmr1, and Fto 172 in the heart tissue was quantified by real-time quantitative polymerase chain reaction 173 assay according to our previous protocol[43, 44]. The primer sequences are listed in 174 Table S1.

175

176 2.8 Statistical analysis

177 The experimental data are expressed as the mean and standard deviation and were 178 analyzed by Prism (version 9.5.0, GraphPad, CA, USA) with a t test and one-way 179 analysis of variance if applicable. P < 0.05 was considered statistically significant.

All data processing and analysis were completed through R (version 4.1.0) with independent Student t test, Mann Whitney U test (Wilcoxon rank sum test), Chi square test or Fisher exact test, if applicable. All P < 0.05 bilaterally was considered statistically significant.

184 3. Results

185 3.1 m6A-related regulators in HCM

- 186 We obtained 20 m6A-related regulators in HCM. Among them, there were 6 writers
- 187 (METTL3, ZC3H13, METTL14, CBLL1, WTAP, and RBM15), 2 erasers (FTO and
- 188 ALKBH5), and 12 readers (YTHDC1, YTHDC2, ELAVL1, YTHDF1, LRPPRC,

189 YTHDF2, FMR1, YTHDF3, HNRNPC, HNRNPA2B1, IGF2BP2, and IGF2BP3).

190 The chromosomal locations of 20 m6A-related regulators were shown in Figure 2A.

191 A total of 8 m6A-related regulators differentially expressed, YTHDC1, HNRNPC,

and FMR1 were up-regulated in HCM and YTHDC2, FTO, WTAP, IGF2BP2, and

193 IGF2BP3 were down-regulated in HCM (Figure 2B&C). Through linear regression

analysis, we found that the expression of CBLL1, ZC3H13, METTL3, and METTL14

195 was highly positively correlated with FTO (P < 0.05, < 0.0001, < 0.0001, and <

196 0.0001, respectively), the expression of RBM15 was highly negatively correlated with

197 FTO (P < 0.0001), and the expression of CBLL1 and METTL14 was highly

198 negatively correlated with ALKBH5 (P < 0.001 and < 0.01, respectively) (Figure 2D).

199

200 3.2 Random forest model and nomogram

In the training cohort, we build the random forest model (Figure 3A). FTO, FMR1, IGF2BP3, YTHDC1, and IGF2BP2 were top 5 important m6A-related regulators in HCM (Figure 3B). The residual plots in the training and validation cohorts were shown in Figure 3C&D (P < 0.0001 and < 0.001, respectively). Moreover, The ROC curves indicated that the model performed well (AUC = 1 and 0.86 in the training and validation cohorts, respectively) (Figure 3E).

207

We constructed a nomogram based on top 5 important m6A-related regulators in HCM (Figure 4A) and calibration curve, decision curve analysis, and ROC curve showed that the performance of nomogram was acceptable (Figure 4B~D).

211

Correlation analysis showed that FMR1 and T cells follicular helper, FTO and B cells
naïve, Monocytes, T cells CD8, T cells regulatory (Tregs), IGF2BP2 and Dendritic
cells resting, T cells gamma delta, T cells regulatory (Tregs), IGF2BP3 and Dendritic
cells activated, Dendritic cells resting, T cells gamma delta, YTHDC1 were strongly
correlated with T cells CD8 (Figure 4-1).

217

218 3.3 m6A subtype construction

When k = 2, the classification was reliable and stable (Figure 5A~F). Among 10 hubgenes, NFKB1, PSMC4, PSMA4, PSMA2, and PSMA6 were dys-regulated in ClusterA and ClusterB (P < 0.001, < 0.01, < 0.001, < 0.01, and < 0.001, respectively) (Figure 5). Therefore, we divided the samples into ClusterA and ClusterB. Further, we obtained 329 differentially expressed genes (154 genes were up-regulated and 175 genes were down-regulate) (Figure 5G&H).

225

226 Through enrichment analysis of 329 differentially expressed genes, we found that 227 homophilic cell adhesion via plasma membrane adhesion molecules, positive 228 regulation of necrotic cell death, respiratory electron transport chain, glycosylation, 229 necrotic cell death, regulation of necrotic cell death, energy derivation by oxidation of 230 organic compounds, mitochondrial ATP synthesis coupled electron transport, cellular 231 response to osmotic stress, and positive regulation of amino acid transport were 232 enriched in biological process; endocytic vesicle lumen, autolysosome, respiratory 233 chain complex, Golgi cis cisterna, haptoglobin-hemoglobin complex, mitochondrial 234 respirasome, mitochondrial respiratory chain complex IV, hemoglobin complex, 235 Golgi cisterna membrane, and ficolin-1-rich granule membrane were enriched in 236 cellular component; Rac GTPase binding, fibronectin binding, inorganic anion 237 intramolecular transmembrane activity, transporter transferase activity, 238 phosphotransferases, haptoglobin binding, RAGE receptor binding, pre-mRNA 239 intronic binding, copper ion binding, oxygen binding, and oxygen carrier activity, 240 were enriched in molecular function (Figure 6A). Calcium signaling pathway,

Sphingolipid metabolism, Gastric acid secretion, Leukocyte transendothelial migration, Neuroactive ligand-receptor interaction, Malaria, and Proximal tubule bicarbonate reclamation were enriched in Kyoto Encyclopedia of Genes and Genomes (Figure 6B). Calcium signaling pathway and Leukocyte transendothelial migration were visualized in Figure 6C&D. Through gene set enrichment analysis, pathways related to infection, oxidative stress, immunity, and amino acid metabolism were enriched (Figure 6E).

248

Through protein-protein interaction analysis of 329 differentially expressed genes, we obtained a network consisting of 143 genes and 184 connections (Figure 7A). Next, we got sub-networks consisting of the top 20 and 10 genes (Figure 7B&C).

252

Furthermore, we constructed Hubgene-chemical network, Hubgene-microRNA network, and Hubgene-transcription factor network of the top 10 hubgenes. Hubgenechemical network included 574 nodes (10 hubgenes and 564 chemicals) and 837 edges (Figure 8A), Hubgene-microRNA network included 131 nodes (9 hubgenes and 121 microRNAs) and 132 edges (Figure 8B), Hubgene-transcription factor network included 181 nodes (10 hubgenes and 171 transcription factors) and 284 edges (Figure 8C).

260

261 3.4 Immune subtype construction

When k = 2, the classification was reliable and stable (Figure 9A~D). Therefore, we divided the samples into ImmuClusterA and ImmuClusterB. Further, we obtained 50 differentially expressed genes (15 genes were up-regulated and 35 genes were downregulated) (Figure 9E). Among top 10 hubgenes, NFKB1, PSMD10, and PSMA6 negatively correlated with most immune cell infiltration and PSMC4 and PSMA4 positively correlated with most immune cell infiltration (Figure 9F). Interestingly, NFKB1, PSMD10, PSMA6, PSMC4, and PSMA4 were dys-regulated in

269 ImmuClusterA and ImmuClusterB (P < 0.001, < 0.01, < 0.001, < 0.01, and < 0.01,

270 respectively) (Figure 9G), suggesting these genes may be immune-related targets.

271

272 We used the CIBERSORT algorithm to analyze the proportion of immune subsets in 273 patients with HCM, and constructed a map of 22 immune cells in HCM (Figure 10A) 274 and the correlation of 22 immune cells (Figure 10B). We analyzed the correlation 275 between top 10 hubgenes and immune cells, and found that NFKB1 was negatively 276 correlated with CD8⁺ T cells and T regulatory cells (Figure 10 C&D), PSMA4 was 277 negatively correlated with B naïve cells and positively correlated CD8⁺ T cells 278 (Figure 10E&F), PSMA6 was negatively correlated with mast cells and T regulatory 279 cells (Figure 10 G&H), PSMC4 was positively correlated T follicular helper cells and 280 negatively correlated with T gamma delta cells (Figure 10 I&J), PSMD7 and PSMD8 281 were negatively correlated with T gamma delta cells (Figure 10 K&L) PSMD10 was 282 negatively correlated with and T regulatory cells (Figure 10 M).

283

284 3.5 Hubgene subtype construction

When k = 2, the classification was reliable and stable (Figure 11A~E). We divided the samples into GeneClusterA and GeneClusterB. And through principal component analysis, it was found that the classification was significantly different (Figure 11F). Among 10 hubgenes, NFKB1, PSMA4, and PSMA6 were dys-regulated between GeneClusterA and GeneClusterB (P < 0.001, < 0.01, and < 0.001, respectively) (Figure 11G).

291

292 3.6 Experimental Validation

293

Relative mRNA levels of hypertrophy marker genes (ANP, BNP, and MYH7) and Hnrnpc, Fmr1, Fto in heart tissues from mice at four weeks after sham operations or TAC surgery (n=6). For statistical analysis, nonparametric statistical analysis was performed using the Mann-Whitney test for two groups.

298 4. Discussion

299 HCM is mainly caused by the mutations in sarcomere genes[45]. Relevant genetic 300 testing has been recommended by guidelines and has promoted the diagnosis of HCM 301 to a certain extent. However, more and more studies show that the clinical 302 characteristics observed in patients with HCM is not all caused by abnormal 303 sarcomeric proteins[2, 46, 47]. Therefore, it is necessary to explore alternative 304 molecular mechanisms of HCM and identify more valuable biomarkers by utilizing 305 contemporary methods to analyze biological complexity[48]. Here, we firstly 306 identified 20 m6A-related regulators in HCM and constructed the m6A, immune, and 307 hubgene subtypes. Finally, the key findings were validated the molecular biology 308 experiments.

309 m6A is required for the formation of a nuclear body mediated by phase separation that 310 maintains mRNA stability[49]. YTHDC1 mediates export of methylated mRNA from 311 the nucleus to the cytoplasm and knockdown of YTHDC1 results in an extended 312 residence time for nuclear m6A-containing mRNA, with an accumulation of 313 transcripts in the nucleus and accompanying depletion within the cytoplasm[50]. 314 YTHDC2 is a powerful endogenous ferroptosis inducer and targets SLC3A2 and 315 SLC7A11[51, 52]. HNRNPC is attributed to the function of controlling the 316 endogenous double-stranded RNA and the downstream interferon response[53]. 317 Sequence-specific mRNAs instruct FMR1-ribonucleoprotein granules to undergo a 318 dynamic phase switch, thus contributing to maternal mRNA decay. FTO mediated the 319 m6A level of LINC00022 and MALAT to promote the tumorigenesis[54, 55]. 320 WTAP-guided m6A modification contributes to the progression of hepatocellular 321 carcinoma via the HuR-ETS1-p21/p27 axis[56]. IGF2BP2/3 m6A promotes 322 vasculogenic mimicry in colorectal cancer via PI3K/AKT and ERK1/2 signaling[57] 323 and attenuates the detrimental effect of irradiation on lung adenocarcinoma[58]. Here, 324 we found that these m6A-related regulators were differentially expressed in HCM. 325 Moreover, we illustrated the correlations of certain m6A-related regulators. Then we

326 built the high-fidelity random forest model and used the top 5 important m6A-related 327 regulators in HCM (namely FTO, FMR1, IGF2BP3, YTHDC1, and IGF2BP2) to 328 construct the nomogram, which is a good predictor for the risk of HCM. According to 329 the expression of these 5 m6A-related regulators, we constructed the m6A subtype. 330 Based on the 329 differential genes of the two subtypes, we enriched many biological 331 processes and signaling pathways known to be associated with HCM. Activation of 332 CaMK-signaling pathway may be involved in the pathophysiology of HCM[59]. Post-333 translational activation of the CaMKII pathway is specific to sarcomere mutation-334 positive HCM, whereas sarcoplasmic endoplasmic reticular calcium ATPase 2 abundance and sarcoplasmic reticulum Ca²⁺ uptake are depressed in both sarcomere 335 336 mutation-positive and -negative HCM[60]. HCM is characterized by enhanced 337 oxidative stress, which achieves its highest values in the presence of LVOT 338 obstruction in HCM patients[61] and reducing oxidative stress can be a viable 339 therapeutic approach to attenuating the severity of cardiac dysfunction in HCM and 340 prevent its progression[62]. Importantly, we also enriched oxidative stress-related 341 signaling pathways. After protein-protein interaction of 329 differentially expressed 342 genes, Hubgene-chemical network, Hubgene-microRNA network, and Hubgene-343 transcription factor network of the top 10 hubgenes among 329 differentially 344 expressed genes were sequentially constructed, which not only provide ideas for the 345 pathogenesis of HCM, but also give insights into the treatment of HCM.

346 m6A is closely connected to immune cell infiltration[20, 21] and the immune system 347 engage in the HCM mechanisms[22, 23]. After m6A subtype, we constructed immune 348 subtype according to the immune cell infiltration levels. We demonstrated the 349 correlation of some differential genes with immune cell infiltration and various 350 immune cells, which further deepens the understanding of immunity in the occurrence 351 and development of HCM. And then hubgene subtype classification was constructed 352 based on the expression of top 10 hubgenes and NFKB1, PSMA4, and PSMA6 were 353 dys-regulated between hubgene subtypes.

354 This study establishes a clinically accessible model for predicting HCM risk through 355 bioinformatics analysis using transcriptome datasets of HCM patients and healthy 356 controls, and furthers the understanding of the molecular mechanisms of m6A and 357 immunity in HCM. Nonetheless, our study still has some limitations and inadequacies. 358 Firstly, although we used different datasets for the analysis, because this was a 359 reanalysis based on the existing data, we could not fully obtain more pathological, 360 clinical and prognostic information of the dataset, which led us to build a risk model 361 later, rather than provide more evidence for treatment or prognosis. In addition, we 362 constructed different networks, which have a certain role in promoting the 363 pathogenesis and clinical treatment of HCM. Although we have carried out biological 364 experiments to verify important results, most of the results we obtained are based on 365 computer analysis. Many basic experiments and clinical experiments are warranted to 366 validate our findings.

367 5. Conclusion

The systematic analysis of the transcriptional profiles of HCM and exploration of the potential underlying molecular mechanisms led to the identification of m6A, immune and hubgene subtype of HCM. Based on these, a risk assessment model of HCM was developed that brings a novel understanding to the current understanding of HCM.

372 Abbreviations

373

374

375 Declarations

376 Ethics approval and consent to participate

All animal experiment was conducted in accordance with the internationally acceptedprinciples for laboratory animal use and care and was reviewed and approved by the

- 379 Experimental Animal Center of Zhengzhou University (Zhengzhou, China) (ZZU-
- 380 LAC20220311[23]). Our study is reported in accordance with the Animal Research:
- 381 Reporting of *in vivo* Experiments guidelines.

- 382 Consent for publication
- 383 Not applicable.
- 384 Availability of data and materials
- 385 All data generated or analyzed during this study are included in this published article
- and its supplementary information files.
- 387 Competing interests
- 388 Not applicable.
- 389 Funding
- 390 This work was partly funded by.
- 391 Authors contributions
- 392 BL and NG conceived, designed, and planned the study. BL and NG acquired and
- analyzed the data. BL completed the experiments. BL and NG interpreted the results.
- 394 BL drafted the manuscript and NG contributed to the critical revision of the
- 395 manuscript. All authors read and approved the final manuscript.
- 396 Acknowledgments
- 397 We are grateful to all research scientists who participated in the aforementioned
- databases.
- 399 References
- Palandri C, Santini L, Argirò A, Margara F, Doste R, Bueno-Orovio A,
 Olivotto I, Coppini R: Pharmacological Management of Hypertrophic
 Cardiomyopathy: From Bench to Bedside. Drugs 2022, 82(8):889-912.
- 2. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL,
 Hung J, Joglar JA, Kantor P *et al*: 2020 AHA/ACC Guideline for the
 Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy:
 A Report of the American College of Cardiology/American Heart
 Association Joint Committee on Clinical Practice Guidelines. *Circulation*2020, 142(25):e558-e631.
- 409 3. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, 410 Hagege AA, Lafont A, Limongelli G, Mahrholdt H et al: 2014 ESC 411 Guidelines on diagnosis and management of **hypertrophic** 412 cardiomyopathy: the Task Force for the Diagnosis and Management of 413 Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). European heart journal 2014, 35(39):2733-2779. 414
- 4. Covella M, Rowin EJ, Hill NS, Preston IR, Milan A, Opotowsky AR, Maron
 416 BJ, Maron MS, Maron BA: Mechanism of Progressive Heart Failure and

417		Significance of Pulmonary Hypertension in Obstructive Hypertrophic
418		Cardiomyopathy . <i>Circ Heart Fail</i> 2017, 10 (4):e003689.
419	5.	Ommen SR, Semsarian C: Hypertrophic cardiomyopathy: a practical
420	5.	approach to guideline directed management. Lancet (London, England)
421		2021, 398 (10316):2102-2108.
422	6.	Geisterfer-Lowrance AA, Christe M, Conner DA, Ingwall JS, Schoen FJ,
423		Seidman CE, Seidman JG: A mouse model of familial hypertrophic
424		cardiomyopathy. Science (New York, NY) 1996, 272(5262):731-734.
425	7.	Pagiatakis C, Di Mauro V: The Emerging Role of Epigenetics in
426		Therapeutic Targeting of Cardiomyopathies. Int J Mol Sci 2021,
427		22 (16):8721.
428	8.	Takeda Y, Demura M, Yoneda T, Takeda Y: DNA Methylation of the
429		Angiotensinogen Gene, AGT, and the Aldosterone Synthase Gene,
430		CYP11B2 in Cardiovascular Diseases. Int J Mol Sci 2021, 22(9):4587.
431	9.	Liu C, Gu L, Deng W-J, Meng Q-C, Li N, Dai G, Yu S, Fang H: N6-
432		Methyladenosine RNA Methylation in Cardiovascular Diseases. Frontiers
433		in cardiovascular medicine 2022, 9 :887838.
434	10.	Chien C-S, Li JY-S, Chien Y, Wang M-L, Yarmishyn AA, Tsai P-H, Juan C-
435		C, Nguyen P, Cheng H-M, Huo T-I et al: METTL3-dependent N(6)-
436		methyladenosine RNA modification mediates the atherogenic
437		inflammatory cascades in vascular endothelium. Proc Natl Acad Sci U S A
438		2021, 118 (7):e2025070118.
439	11.	Li B-C, Zhang T, Liu M-X, Cui Z, Zhang Y-H, Liu M, Liu Y, Sun Y, Li M,
440		Tian Y et al: RNA N(6)-methyladenosine modulates endothelial
441		atherogenic responses to disturbed flow in mice. <i>eLife</i> 2022, 11 :e69906.
442	12.	Su X, Shen Y, Jin Y, Kim I-M, Weintraub NL, Tang Y: Aging-Associated
443		Differences in Epitranscriptomic m6A Regulation in Response to Acute
444		Cardiac Ischemia/Reperfusion Injury in Female Mice. Front Pharmacol
445		2021, 12 :654316.
446	13.	Mo X-B, Lei S-F, Zhang Y-H, Zhang H: Examination of the associations
447		between m(6)A-associated single-nucleotide polymorphisms and blood
448		pressure. Hypertension research : official journal of the Japanese Society of
449		Hypertension 2019, 42 (10):1582-1589.
450	14.	Cheng P-K, Han H-K, Chen F-L, Cheng L, Ma C, Huang H, Chen C, Li H,
451		Cai H, Huang H et al: Amelioration of acute myocardial infarction injury
452		through targeted ferritin nanocages loaded with an ALKBH5 inhibitor.
453		<i>Acta biomaterialia</i> 2022, 140 :481-491.
454	15.	Qian B-H, Wang P, Zhang D-H, Wu L: m6A modification promotes miR-
455		133a repression during cardiac development and hypertrophy via
456	16	IGF2BP2 . Cell Death Discov 2021, 7 :157-157.
457	16.	Mathiyalagan P, Adamiak M, Mayourian J, Sassi Y, Liang Y, Agarwal N, Jha
458		D, Zhang S, Kohlbrenner E, Chepurko E <i>et al</i> : FTO-Dependent $N(6)$ -

450		Matheledenesing Developer Carding Engeting Device Developing and
459		Methyladenosine Regulates Cardiac Function During Remodeling and Remain Circulation 2010, 120(4):518,522
460	17	Repair . Circulation 2019, 139 (4):518-532.
461	17.	Zhang B-J, Xu Y-M, Cui X-T, Jiang H, Luo W, Weng X, Wang Y, Zhao Y,
462		Sun A, Ge J: Alteration of m6A RNA Methylation in Heart Failure With
463		Preserved Ejection Fraction . Frontiers in cardiovascular medicine 2021,
464	10	8 :647806.
465	18.	Shulman Z, Stern-Ginossar N: The RNA modification N(6)-
466		methyladenosine as a novel regulator of the immune system. Nature
467	10	<i>immunology</i> 2020, 21 (5):501-512.
468	19.	Wang Y-N, Yu C-Y, Jin H-Z: RNA N(6)-Methyladenosine Modifications
469		and the Immune Response. Journal of immunology research 2020,
470	•	2020 :6327614.
471	20.	Liang C-Z, Wang S, Zhang M, Li T: Diagnosis, clustering, and immune cell
472		infiltration analysis of m6A-related genes in patients with acute
473		myocardial infarction-a bioinformatics analysis. Journal of thoracic
474		<i>disease</i> 2022, 14 (5):1607-1619.
475	21.	Yin F-X, Zhang H, Guo P-P, Wu Y, Zhao X, Li F, Bian C, Chen C, Han Y,
476		Liu K: Comprehensive Analysis of Key m6A Modification Related Genes
477		and Immune Infiltrates in Human Aortic Dissection. Frontiers in
478	~~	cardiovascular medicine 2022, 9 :831561.
479	22.	Kardaszewicz B, Rogala E, Tendera M, Kardaszewicz P, Jarzab J:
480		Circulating immune complexes in hypertrophic cardiomyopathy and
481	• •	ischemic heart disease. Kardiologia polska 1991, 34 (1):21-24.
482	23.	Lüscher TF: An update on cardiomyopathies: immune-mediated diseases,
483		sarcoidosis, and peripartum and hypertrophic cardiomyopathies during
484	.	pregnancy. European heart journal 2017, 38 (35):2635-2638.
485	24.	Wang Z-Q, Ruan H-Y, Li L-Y, Wei X, Zhu Y, Wei J, Chen X, He S:
486		Assessing the relationship between systemic immune-inflammation index
487		and mortality in patients with hypertrophic cardiomyopathy. Upsala
488		journal of medical sciences 2021, 126 .
489	25.	Maron BA, Wang R-S, Shevtsov S, Drakos SG, Arons E, Wever-Pinzon O,
490		Huggins GS, Samokhin AO, Oldham WM, Aguib Y et al: Individualized
491		interactomes for network-based precision medicine in hypertrophic
492		cardiomyopathy with implications for other clinical pathophenotypes. Nat
493		<i>Commun</i> 2021, 12 (1):873-873.
494	26.	Zhou J-G, Liang B, Jin S-H, Liao H-L, Du G-B, Cheng L, Ma H, Gaipl US:
495		Development and Validation of an RNA-Seq-Based Prognostic Signature
496	• =	in Neuroblastoma. Front Oncol 2019, 9 :1361.
497	27.	Zhou J-G, Liang B, Liu J-G, Jin S-H, He S-S, Frey B, Gu N, Fietkau R, Hecht
498		M, Ma H et al: Identification of 15 IncRNAs Signature for Predicting
499		Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1
500		Monotherapy . Cells 2021, 10 (5):977.

501	20	
501	28.	Kainuma A, Ning Y, Kurlansky PA, Wang AS, Latif F, Sayer GT, Uriel N,
502		Kaku Y, Naka Y, Takeda K: Predictors of one-year outcome after cardiac
503		re-transplantation: Machine learning analysis. Clinical transplantation
504	• •	2022:e14761.
505	29.	Lu W-C, Chen H, Liang B, Ou C-P, Zhang M, Yue Q, Xie J: Integrative
506		Analyses and Verification of the Expression and Prognostic Significance
507		for RCN1 in Glioblastoma Multiforme. Front Mol Biosci 2021, 8:736947.
508	30.	Zhang M-W, Chen H, Liang B, Wang X-Z, Gu N, Xue F-Q, Yue Q-Y, Zhang
509		Q-Y, Hong J-S: Prognostic Value of mRNAsi/Corrected mRNAsi
510		Calculated by the One-Class Logistic Regression Machine-Learning
511		Algorithm in Glioblastoma Within Multiple Datasets. Front Mol Biosci
512		2021, 8 :777921.
513	31.	Wilkerson MD, Hayes DN: ConsensusClusterPlus: a class discovery tool
514		with confidence assessments and item tracking. Bioinformatics 2010,
515		26 (12):1572-1573.
516	32.	Yu G-C, Wang L-G, Han Y, He Q-Y: clusterProfiler: an R package for
517		comparing biological themes among gene clusters. Omics : a journal of
518		<i>integrative biology</i> 2012, 16 (5):284-287.
519	33.	Luo W-J, Brouwer C: Pathview: an R/Bioconductor package for pathway-
520		based data integration and visualization. Bioinformatics 2013, 29(14):1830-
521		1831.
522	34.	Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P:
523		The Molecular Signatures Database (MSigDB) hallmark gene set
524		collection . Cell Syst 2015, 1 (6):417-425.
525	35.	Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA,
526		Paulovich A, Pomeroy SL, Golub TR, Lander ES et al: Gene set enrichment
527		analysis: a knowledge-based approach for interpreting genome-wide
528		expression profiles . <i>Proc Natl Acad Sci U S A</i> 2005, 102 (43):15545-15550.
529	36.	Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, Doncheva
530		NT, Legeay M, Fang T, Bork P et al: The STRING database in 2021:
531		customizable protein-protein networks, and functional characterization of
532		user-uploaded gene/measurement sets. Nucleic acids research 2021,
533		49 (D1):D605-D612.
534	37.	Chin C-H, Chen S-H, Wu H-H, Ho C-W, Ko M-T, Lin C-Y: cytoHubba:
535		identifying hub objects and sub-networks from complex interactome.
536		BMC systems biology 2014, 8 Suppl 4(Suppl 4):S11.
537	38.	Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N,
538		Schwikowski B, Ideker T: Cytoscape: a software environment for
539		integrated models of biomolecular interaction networks. Genome Res 2003,
540		13 (11):2498-2504.
541	39.	Zhou G-Y, Soufan O, Ewald J, Hancock REW, Basu N, Xia J-G:
542		NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene

543		expression profiling and meta-analysis. Nucleic acids research 2019,
544		47 (W1):W234-w241.
545	40.	Huang H-Y, Lin Y-C-D, Li J, Huang K-Y, Shrestha S, Hong H-C, Tang Y,
546		Chen Y-G, Jin C-N, Yu Y et al: miRTarBase 2020: updates to the
547		experimentally validated microRNA-target interaction database. Nucleic
548		acids research 2020, 48 (D1):D148-D154.
549	41.	Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD,
550		Diehn M, Alizadeh AA: Robust enumeration of cell subsets from tissue
551		expression profiles. Nat Methods 2015, 12(5):453-457.
552	42.	Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ,
553		Ross J, Jr., Chien KR: Segregation of atrial-specific and inducible
554		expression of an atrial natriuretic factor transgene in an in vivo murine
555		model of cardiac hypertrophy. Proc Natl Acad Sci U S A 1991, 88(18):8277-
556		8281.
557	43.	Liang B, Zhang X-X, Li R, Gu N: Guanxin V protects against ventricular
558		remodeling after acute myocardial infarction through the interaction of
559		TGF-β1 and Vimentin . <i>Phytomedicine</i> 2022, 95 :153866.
560	44.	Liang B, Zhang X-X, Li R, Zhu Y-C, Tian X-J, Gu N: Guanxin V alleviates
561		acute myocardial infarction by restraining oxidative stress damage,
562		apoptosis, and fibrosis through the TGF-β1 signalling pathway.
563		<i>Phytomedicine</i> 2022, 100 :154077.
564	45.	van der Velde N, Huurman R, Hassing HC, Budde RPJ, van Slegtenhorst MA,
565		Verhagen JMA, Schinkel AFL, Michels M, Hirsch A: Novel Morphological
566		Features on CMR for the Prediction of Pathogenic Sarcomere Gene
567		Variants in Subjects Without Hypertrophic Cardiomyopathy. Frontiers in
568		cardiovascular medicine 2021, 8 :727405.
569	46.	Bos JM, Will ML, Gersh BJ, Kruisselbrink TM, Ommen SR, Ackerman MJ:
570		Characterization of a phenotype-based genetic test prediction score for
571		unrelated patients with hypertrophic cardiomyopathy. Mayo Clinic
572		proceedings 2014, 89 (6):727-737.
573	47.	Neubauer S, Kolm P, Ho CY, Kwong RY, Desai MY, Dolman SF,
574		Appelbaum E, Desvigne-Nickens P, DiMarco JP, Friedrich MG et al: Distinct
575		Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM
576		Registry. Journal of the American College of Cardiology 2019, 74(19):2333-
577		2345.
578	48.	Zheng X-F, Liu G-Y, Huang R-N: Identification and Verification of
579		Feature Immune-Related Genes in Patients With Hypertrophic
580		Cardiomyopathy Based on Bioinformatics Analyses. Frontiers in
581		cardiovascular medicine 2021, 8:752559.
582	49.	Cheng Y-M, Xie W, Pickering BF, Chu KL, Savino AM, Yang X, Luo H,
583		Nguyen DT, Mo S, Barin E et al: N(6)-Methyladenosine on mRNA

584		facilitates a phase-separated nuclear body that suppresses myeloid
585		leukemic differentiation. <i>Cancer cell</i> 2021, 39 (7):958-972.e958.
586	50.	Roundtree IA, Luo G-Z, Zhang Z-J, Wang X, Zhou T, Cui Y, Sha J, Huang X,
587		Guerrero L, Xie P et al: YTHDC1 mediates nuclear export of N(6)-
588		methyladenosine methylated mRNAs. <i>eLife</i> 2017, 6:e31311.
589	51.	Ma L-F, Chen T-X, Zhang X, Miao Y, Tian X, Yu K, Xu X, Niu Y, Guo S,
590		Zhang C et al: The m(6)A reader YTHDC2 inhibits lung adenocarcinoma
591		tumorigenesis by suppressing SLC7A11-dependent antioxidant function.
592		<i>Redox biology</i> 2021, 38 :101801.
593	52.	Ma L-F, Zhang X, Yu K-K, Xu X, Chen T, Shi Y, Wang Y, Qiu S, Guo S, Cui
594		J et al: Targeting SLC3A2 subunit of system X(C)(-) is essential for m(6)A
595		reader YTHDC2 to be an endogenous ferroptosis inducer in lung
596		adenocarcinoma. Free radical biology & medicine 2021, 168:25-43.
597	53.	Wu Y-S, Zhao W-W, Liu Y, Tan X, Li X, Zou Q, Xiao Z, Xu H, Wang Y,
598		Yang X: Function of HNRNPC in breast cancer cells by controlling the
599		dsRNA-induced interferon response. The EMBO journal 2018,
600		37 (23):e99017.
601	54.	Cui Y-B, Zhang C-Y, Ma S-S, Li Z, Wang W, Li Y, Ma Y, Fang J, Wang Y,
602		Cao W et al: RNA m6A demethylase FTO-mediated epigenetic up-
603		regulation of LINC00022 promotes tumorigenesis in esophageal
604		squamous cell carcinoma. Journal of experimental & clinical cancer
605		research : CR 2021, 40 (1):294.
606	55.	Tao L, Mu X-Y, Chen H-G, Jin D, Zhang R, Zhao Y, Fan J, Cao M, Zhou Z:
607		FTO modifies the m6A level of MALAT and promotes bladder cancer
608		progression. Clinical and translational medicine 2021, 11(2):e310.
609	56.	Chen Y-H, Peng C-H, Chen J-R, Chen D, Yang B, He B, Hu W, Zhang Y, Liu
610		H, Dai L et al: WTAP facilitates progression of hepatocellular carcinoma
611		via m6A-HuR-dependent epigenetic silencing of ETS1. Molecular cancer
612		2019, 18 (1):127.
613	57.	Liu X, He H-J, Zhang F-W, Hu X, Bi F, Li K, Yu H, Zhao Y, Teng X, Li J et
614		al: m6A methylated EphA2 and VEGFA through IGF2BP2/3 regulation
615		promotes vasculogenic mimicry in colorectal cancer via PI3K/AKT and
616		ERK1/2 signaling. Cell death & disease 2022, 13(5):483.
617	58.	Hao C-C, Xu C-Y, Zhao X-Y, Luo J-N, Wang G, Zhao L-H, Ge X, Ge X-F:
618		Up-regulation of VANGL1 by IGF2BPs and miR-29b-3p attenuates the
619		detrimental effect of irradiation on lung adenocarcinoma. Journal of
620		experimental & clinical cancer research : CR 2020, 39 (1):256.
621	59.	Chen P, Li Z, Nie J, Wang H, Yu B, Wen Z, Sun Y, Shi X, Jin L, Wang D-W:
622		MYH7B variants cause hypertrophic cardiomyopathy by activating the
623		CaMK-signaling pathway. Science China Life sciences 2020, 63(9):1347-
624		1362.

625	60.	Helms AS, Alvarado FJ, Yob J, Tang VT, Pagani F, Russell MW, Valdivia
626		HH, Day SM: Genotype-Dependent and -Independent Calcium Signaling
627		Dysregulation in Human Hypertrophic Cardiomyopathy. Circulation 2016,
628		134 (22):1738-1748.
629	61.	Dimitrow PP, Undas A, Wołkow P, Tracz W, Dubiel JS: Enhanced oxidative
630		stress in hypertrophic cardiomyopathy. Pharmacological reports : PR 2009,
631		61 (3):491-495.
632	62.	Hassoun R, Budde H, Zhazykbayeva S, Herwig M, Sieme M, Delalat S,
633		Mostafi N, Gömöri K, Tangos M, Jarkas M et al: Stress activated signalling
634		impaired protein quality control pathways in human hypertrophic
635		cardiomyopathy. International journal of cardiology 2021, 344:160-169.
636	Tabl	les

- 637 Table 1. Details of datasets.

638

639 Figure legends

640 Figure 1. Flow chart of this study.

641 Figure 2. The landscape of m6A-related regulators in HCM. A. The chromosomal

642 locations of 20 m6A-related regulators. B. Heatmap of expression of 20 m6A-related

regulators. C. Histogram of expression of 20 m6A-related regulators. *P < 0.05, **P

644 < 0.01, ***P < 0.001. D. The correlation between writers and erasers.

645 Figure 3. Random forest model construction. A. Model was built in the training cohort.

646 B. Importance of m6A-related regulators based on the model. C. Residual plot

647 showing the distribution of residuals in the training cohort. D. Residual plot showing

648 the distribution of residuals in the validation cohort. E. The ROC curves showing the

649	accuracy	of the	model	in tl	he ti	raining	and	validation	cohorts.

650 Figure 4. Construction of the nomogram. A. Construction of the nomogram based on

top 5 important m6A-related regulators in HCM. B. Calibration curve. C. decisioncurve analysis. D. ROC curve.

Figure 4-1. Correlation between top 5 candidate m6A regulators and immune-relatedcell types.

655 Figure 5. m6A subtype construction based on the expression of top 5 m6A-related 656 regulators. A. Matrix heatmap for k = 2. B. Matrix heatmap for k = 3. C. Matrix 657 heatmap for k = 4. D. Consistent cumulative distribution function plot. This figure 658 allows a user to determine at what number of clusters, k, the cumulative distribution 659 function reaches an approximate maximum, thus consensus and cluster con dence is at 660 a maximum at this k. E. Delta area plot. The delta area score (y-axis) indicates the 661 relative increase in cluster stability. F. Tracking plot. This plot provides a view of 662 item cluster membership across different k and enables a user to track the history of 663 clusters relative to earlier clusters. G. Heatmap for differentially expressed genes. H. 664 Volcano plot for differentially expressed genes. I. Difference analysis of top 10 665 hubgene in m6A subtype classification.

Figure 6. Functional enrichment of 329 differentially expressed genes. A. Top 10
gene ontology terms. B. Top 7 Kyoto Encyclopedia of Genes and Genomes terms. C.
Visualization of Calcium signaling pathway. D. Visualization of Leukocyte
transendothelial migration. E. Gene set enrichment analysis terms.

Figure 7. Protein-protein interaction network. A. Protein-protein interaction network
among those genes with a score greater than 0.6. B. Protein-protein interaction
network of top 20 hubgenes. C. Protein-protein interaction network of top 10
hubgenes.

Figure 8. Networks of the top 10 hubgenes. A. Hubgene-chemical network. B.
Hubgene-microRNA network. C. Hubgene-transcription factor network.

Figure 9. Immune subtype construction. A. Matrix heatmap for k = 2. B. Matrix heatmap for k = 3. C. Consistent cumulative distribution function plot. This figure allows a user to determine at what number of clusters, k, the cumulative distribution function reaches an approximate maximum, thus consensus and cluster con dence is at a maximum at this k. D. Delta area plot. The delta area score (y-axis) indicates the relative increase in cluster stability. E. Heatmap for differentially expressed genes. F.

682 The correlation between top 10 hubgenes and immune-related cell types. G.

Histogram of expression of top 10 hubgenes. **P < 0.01, ***P < 0.001.

684 Figure 10. CIBERSORT immune cell infiltration analysis and correlation analysis 685 between hubgene and immune cells. A. Barplot showing the proportions of 22 686 immune cells in a sepsis sample. The column in the figure is a sample. B. Correlation 687 heat map of 22 immune cells infiltration. Blue indicated positive correlation, red 688 indicated negative correlation, the darker the color, the stronger the correlation. C. 689 The correlation between NFKB1 and $CD8^+$ T cells. D. The correlation between 690 NFKB1 and T regulatory cells. E. The correlation between PSMA4 and B naïve cells. 691 F. The correlation between PSMA4 and $CD8^+$ T cells. G. The correlation between 692 PSMA6 and mast cells. H. The correlation between PSMA6 and T regulatory cells. I. 693 The correlation between PSMC4 and T follicular helper cells. J. The correlation 694 between PSMC4 and T gamma delta cells. K. The correlation between PSMD7 and T 695 gamma delta cells. L. The correlation between PSMD8 and T gamma delta cells. M. 696 The correlation between PSMD10 and T regulatory cells.


697 Figure 11. Hubgene subtype construction. A. Matrix heatmap for k = 2. B. Matrix 698 heatmap for k = 3. C. Consistent cumulative distribution function plot. This figure 699 allows a user to determine at what number of clusters, k, the cumulative distribution 700 function reaches an approximate maximum, thus consensus and cluster con dence is at 701 a maximum at this k. D. Delta area plot. The delta area score (y-axis) indicates the 702 relative increase in cluster stability. E. Tracking plot. This plot provides a view of 703 item cluster membership across different k and enables a user to track the history of 704 clusters relative to earlier clusters. F. Principal component analysis. G. Difference 705 analysis of top 10 hubgenes in hubgene subtype classification.


706


707 Additional files


708 Table S1. Primer sequences.


- 709 Figure S1. Datasets collation. A. All samples were pooled before removing batch
- 710 effects. B. All samples were pooled after removing batch effects.




























1	Pathway			Gene	ranks	NI	ES pval	padj
	REACTOME_METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES					2.3	24 1.7e-0	04 7.9e-03
	REACTOME_TRANSLATION					2.0	55 1.8e-0	04 7.9e-03
	REACTOME_SIGNALING_BY_ROBO_RECEPTORS	1010000				2.	17 1.8e-0	04 7.9e-03
	REACTOME_RRNA_PROCESSING					2.5	52 1.8e-0	04 7.9e-03
	REACTOME_INFLUENZA_INFECTION						45 1.8e-0	04 7.9e-03
	KEGG_HUNTINGTONS_DISEASE					uu 1.9	95 1.8e-0	04 7.9e-03
	REACTOME_CELLULAR_RESPONSE_TO_STARVATION	101000				2.0	58 1.8e-0	04 7.9e-03
	WP_NONALCOHOLIC_FATTY_LIVER_DISEASE	10000				u 1.9	94 1.8e-0	04 7.9e-03
	REACTOME_CELLULAR_RESPONSE_TO_CHEMICAL_STRESS	la mo				. 2.0	03 1.8e-0	04 7.9e-03
	REACTOME_REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS	1010000				1 2.0	54 1.8e-0	04 7.9e-03
	KEGG_SMALL_CELL_LUNG_CANCER		110 000			-1.	.82 2.1e-0	04 7.9e-03
	WP_B_CELL_RECEPTOR_SIGNALING_PATHWAY	11		• • • • • • • • • • • • • • • • • • • •		-1.	.83 2.1e-0	04 7.9e-03
	REACTOME_SIGNALING_BY_MET	1 11 1		••••••		-1.	89 2.1e-0	04 7.9e-03
	KEGG_ECM_RECEPTOR_INTERACTION	1 1				-1.	.99 2.1e-0	04 7.9e-03
	PID_AVB3_INTEGRIN_PATHWAY	п				-2.	.13 2.1e-0	04 7.9e–03
	REACTOME_ECM_PROTEOGLYCANS	1 0				-2.	.02 2.1e-0	04 7.9e-03
	PID_FAK_PATHWAY	1	н н			-2.	.11 2.1e-0	04 7.9e-03
	PID_INTEGRIN1_PATHWAY	11 1 1	1 111 - 1	•••		-2.	.03 2.1e-0	04 7.9e-03
	REACTOME_NON_INTEGRIN_MEMBRANE_ECM_INTERACTIONS		0.00			-2.	20 2.1e-0	04 7.9e-03
	REACTOME_MET_PROMOTES_CELL_MOTILITY		11	••		-2.	.24 2.0e-0	04 7.9e-03
		0		5000	10000			

















-

- -